Tiziana Life Sciences Plc Covid-19 Treatment

Thinly traded nano cap Tiziana Life Sciences (NASDAQ:TLSA) is the latest coronavirus play. Shares are up 306% premarket on average volume in reaction to its announcement that candidate TZLS-501 may be a potential treatment for COVID-19 patients at risk of respiratory failure.

The company says it plans to administer TZLS-501, an interleukin 6 (IL-6)-inhibiting monoclonal antibody, using a proprietary formulation technology, adding that excess production of IL-6 is a key driver of chronic inflammation and is believed to play a key role in severe lung damage seen with COVID-19 infection and acute respiratory illness.
Source seekignalpha

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.